More Related Content
Similar to W cll nolily (16)
More from cancerchannel (20)
W cll nolily
- 1. Know [â No] More Cancer
ãã£ãš
2018幎ç
ç£ä¿®ã
å³¶æ ¹å€§åŠå»åŠéš ææ
å³¶æ ¹å€§åŠå»åŠéšéå±ç
é¢å
端ããæ²»çã»ã³ã¿ãŒé· å
Œ è
«çã»è¡æ¶²å
ç§ç§é·
éŽå®® æ·³åž
ç¥ã£ãŠã»ãã
æ
¢æ§ãªã³ãæ§çœè¡ç
ã®ããš
- 2. ANSWER CHRONIC LYMPHOCYTIC LEUKEMIA
ç§ãã»ãã«ç¢ºèªããŠããã¹ã
ããšã¯ãããŸãã
質åããããšãã
åé¡ãèµ·ãã£ããšãã¯ã
誰ã«é£çµ¡ããã°ããã§ãã
ç§ã家æã粟ç¥çã瀟äŒçãª
ãµããŒããåããããšãã¯
ã©ãã«çžè«ããã°ããã§ãã
ç§ãåå ã§ãã
èšåºè©Šéšã¯ãããŸãã
æ²»çã«ãããè²»çšã
æããŠãã ããã
èªå·±è² æ
ã軜æžããæ¹æ³ã¯
ãããŸãã
ç掻äžã®æ³šæç¹ããã£ãã
æããŠãã ãã
æ²»çã«äŒŽãå¯äœçšã
åŸéºçã«ã¯ã©ã®ãããªãã®ã
ãããŸãã
ä»åºãŠãã
çç¶ãçã¿ã軜æžãã
æ¹æ³ã¯ãããŸãã
æ²»çã¯æ¥åžžç掻
ïŒä»äºã家äºã趣å³ïŒã«
ã©ã®ããã«åœ±é¿ããŸãã
æ²»çã®éžæè¢ã«ã€ããŠã
ãã®ç®çãšå©ç¹ãæ¬ ç¹ã
æããŠãã ãã
æ²»çã®æéã¯
ã©ã®ãããã§ãããã
ããã«æ²»çãå§ããå¿
èŠã
ãããŸãã
ç§ã®ç
ç¶ãšé²è¡åºŠã«ã€ããŠ
æããŠãã ãã
è¡æ¶²æ€æ»ãæè²äœæ€æ»ã®
çµæã説æããŠãã ãã
æ²»çæ¹éã決ãããã
å¥åº·ç®¡çããããããããã§ã
èªåã®ç
æ°ã®ç¶æ
ãããç解
ããŠããããšãå¿
èŠã§ãã
次ã®ãããªè³ªåãæ
åœå»ã«
ããŠã¿ãŸãããã
èªåã®ç
æ°ãç解ããããã«ãæ
åœå»ã«è³ªåããŠã¿ãŸããã
- 3. 3
æ
¢æ§ãªã³ãæ§çœè¡ç
ãšã¯ã©ããªç
æ°ã§ãã âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 4
ã©ã®ãããªæ€æ»ã§æ
¢æ§ãªã³ãæ§çœè¡ç
ãšèšºæãããã®ã§ãã âŠâŠâŠâŠâŠâŠâŠâŠ 6
æ
¢æ§ãªã³ãæ§çœè¡ç
ã®ç
æã«ã€ããŠæããŠãã ãã âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 7
æ
¢æ§ãªã³ãæ§çœè¡ç
ã§ã¯ã©ã®ãããªæ²»çãè¡ãããã®ã§ãã âŠâŠâŠâŠâŠâŠâŠâŠ 8
é è¡å¹¹çŽ°è移æ€ã«ã€ããŠæããŠãã ãã âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 11
æ²»çã®äž»ãªå¯äœçšãšãã®å¯ŸåŠæ³ã«ã€ããŠæããŠãã ãã âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 12
åçºãšã¯ã©ã®ãããªç¶æ
ã§ãããã©ã®ãããªæ²»çãè¡ãããŸãã âŠâŠâŠâŠâŠâŠ 14
èŠçãåãããŠãããå°é家ãããŸã âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 15
Patient's Voice âŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠâŠ 9ã10ã13
ã
æ
¢
æ§
ãª
ã³
ã
æ§
çœ
è¡
ç
ã®
ç
ã
ã
ã
ã
ã
ã
æ
¢
æ§
ãª
ã³
ã
æ§
çœ
è¡
ç
ã§
ã
ã
ãš
ã
ã
ã
ã
ã
ãª
ã
ãž
CONTENTS
ããªãã¯ãçªç¶ããæ
¢æ§ãªã³ãæ§çœè¡ç
ããšåãããã
ã©ãããŠããããããããæžæã£ãŠããã®ã§ã¯ãªãã§ããããã
çœè¡ç
ãšããããŠé©ãã
ããªãèªåãããããããã©ããªã£ãŠããŸãã®ãããš
èªåèªçãããäžå®ã«è¥²ããããããã®ã¯ç¡çããããŸããã
ã§ããã©ããåžæã倱ããªãã§ãã ããã
ãã€ãŠäžæ²»ã®ç
ã ã£ãçœè¡ç
ã®æ²»çã¯æ¥ã
é²æ©ããŠããŸãã
æ
¢æ§ãªã³ãæ§çœè¡ç
ã¯äžè¬çã«ã¯ãã£ããé²ãå Žåãå€ãã
ç
æ°ãšã€ããããªããé·çãã§ãã人ãå¢ããŠããŸãã
ãŸãã¯èªåã®ç
æ°ãç
ç¶ã«ã€ããŠç¥ãã
æšæºçãªæ²»çæ³ã«ã€ããŠæ
å ±ãéããããšãéèŠã§ãã
æ£ç¢ºãªæ
å ±ãããªãã®äžå®ã解æ¶ããç
æ°ãšåãåãåæ°ãäžããŠãããŸãã
å¿é
ãªããšãå°ã£ãŠããããšããã£ãããæ
åœå»ã身è¿ãªå»çã¹ã¿ããã«
é æ
®ãªãçžè«ããŸãããã
ãã®ååãçŽåŸã®ããæ²»çãåããããã®æ
å ±æºã®äžã€ãšããŠ
ã掻çšããã ããã幞ãã§ãã
- 5. 5
close-up
è¡æ¶²ãäœãããä»çµã¿ãš CLL
ïŒSmall Lymphocytic LymphomaïŒSLLïŒ
ãšåŒã°ããŸãããåºçŸ©ã§ã¯åãçŸæ£ãšèããã
ãŠãããCLLãšåãæ²»çãè¡ãããŸãã
ããŸããè¡æ¶²äžã«B现èãå¢ããŠãããã®ã®ã
ãã®æ°ãå°ãªãããªã³ãç¯ãèèãèŸèã®è
«
ããªã©ããªãå Žåã¯ãåã¯ããŒã³æ§B现èãª
ã³ ã ç å¢ å çïŒMonoclonal B-cell Lym-
phocytosisïŒ MBLïŒãšåŒã°ããŸããMBL
ããCLLã«ãªãããšãããã®ã§ãå®æçã«æ€
æ»ãåããæ
éã«çµéãã¿ãå¿
èŠããããŸãã
ãCLLã®æ²»çã¯ã»ãã®è¡æ¶²ãããšåæ§ã«è¬
ç©çæ³ãäžå¿ã§ããè¬ã®å¹æãåŸãããããã
é²è¡ããã£ããã§ããããšããã£ãŠãç
æ°ãš
å
±åããªããçãã人ãå¢ããŠããŸãã
ããã ãç°åžžãªB现èãæ¥æ¿ã«å¢æ®ãããªã
ã¿ãŒçå矀ïŒp.4ã³ã©ã ïŒã«ãªã£ãŠããŸã£ã
å Žåã«ã¯ãCLLã®æ²»çã§ã¯ãªããã¢ã°ã¬ãã·
ããªã³ãè
«ãšåãæ²»çãå¿
èŠã§ãã
ãè¡æ¶²äžã«ã¯ãèµ€è¡çãçœè¡çãè¡å°æ¿ãšãã£ã
è¡æ¶²çŽ°èããããŸããçœè¡çã¯ããªã³ãçã奜äž
çã奜é
žçã奜塩åºçãåçã®ç·ç§°ã§ããè¡æ¶²çŽ°
èã¯ã骚ã®äžã«ãã骚é«ã§ãé è¡å¹¹çŽ°èãã骚é«
ç³»åé§çŽ°èããªã³ãç³»åé§çŽ°èãããããããã«
æ©èœãæã€çŽ°èãžãšååïŒå€åïŒããŠäœãããŸãã
ããªã³ãçã¯çœè¡çã®çŽ25ïŒ
ãå ããæåã§ã
ããŒã ãäœã£ãŠçŽ°èããŠã€ã«ã¹ãªã©ã®å€æµãç°ç©
â è¡æ¶²çŽ°èãäœãããä»çµã¿
ïŒè¿ç¿å€§åŠå»åŠéš æŸæå°å»åž«è³æããæ¹å€ïŒ
骚
é è¡å¹¹çŽ°è
骚é«ç³»åé§çŽ°è ãªã³ãç³»åé§çŽ°è
è¡ç®¡
骚é«
ãæ»æããåããæ
ã£ãŠããŸãããã®ããŒã ãæ§
æããŠããã®ãããªã³ãç³»åé§çŽ°èããååãã
B现èïŒBãªã³ãçïŒãT现èïŒTãªã³ãçïŒãšNK
现èã§ããB现èã¯ãç°ç©ãšç¹ç°çã«åå¿ããã¿
ã³ãã¯è³ªã§ããæäœãä»ããŠç°ç©ã®æé€ãè¡ã£ãŠ
ããŸããã
ãCLLã¯ãæçããB现èã®éºäŒåãæè²äœã«å·
ãã€ããŠããåããããšã«ããçºçããç
æ°ã§ãã
çœè¡ç
å³è¡š2 è¡æ¶²çŽ°èã®çæãšCLL
奜äžç
奜é
žç
奜塩åºç
åç
èµ€è¡çè¡å°æ¿ T现è B现è
å¢æ®
ããåãã
B现è
ç°åžžãªB现è
ïŒçœè¡ç
现èïŒã
å¢å
æè²äœç°åžž
éºäŒåç°åžž
ããå
- 8. 8
æ
¢æ§ãªã³ãæ§çœè¡ç
ã®æšæºæ²»çã®æµãå³è¡š7
17pïŒ17çªæè²äœïŒ
æ¬ å€±ãã
UnfitïŒéåžžéå€å€äœµçšçæ³ äžå¯èœïŒ Fit(éåžžéå€å€äœµçšçæ³ å¯èœïŒ
17p
æ¬ å€±ãªã
17p
æ¬ å€±ãã
17p
æ¬ å€±ãªã
çç¶ã掻åæ§ç
æ
ãªãã
ãã€Raiåé¡ïŒïœâ
¡ãBinetåé¡Aã»B
çç¶ã掻åæ§ç
æ
ããã
ãŸãã¯Raiåé¡â
¢ã»â
£ãBinetåé¡C
â»1
2018幎1æçŸåšãä¿éºæ¿èªãããŠããŸãããæ¥æ¬ã§ã¯ãªããã·ããã¯ãªã³ãè
«ã«å¯ŸããŠã¯ä¿éºæ¿èªãããŠãã375 mg/m2
ã䜿çšããã
CLLã§ãããã«æºããŠäœ¿ãããããšããããŸããæµ·å€ã§ã¯ãCLLã«å¯ŸããŠã¯500 mg/m2
ãæšæºçãªäœ¿çšéã§ãã
â»2
2018幎1æçŸåšãã€ãã«ãããã¯ååæ²»çã®ç¬¬1éžæè¬ãšããŠã¯ä¿éºæ¿èªãããŠããŸããã
çµé芳å¯
ãã³ãã ã¹ãã³çæ³Â±
ãªããã·ããâ»1
ã
Fçæ³Â±ãªããã·ããâ»1
ã
æžéFCçæ³Â±
ãªããã·ããâ»1
ã
ã€ãã«ãããâ»2
ã
ã¯ãã©ã ãã·ã«â»1
ãªã©
ãã³ãã ã¹ãã³çæ³Â±
ãªããã·ããâ»1
ã
Fçæ³Â±ãªããã·ããâ»1
ã
æžéFCçæ³Â±
ãªããã·ããâ»1
ã
ã¯ãã©ã ãã·ã«â»1
ãªã©
FCçæ³Â±ãªããã·ããâ»1
ã
ãã³ãã ã¹ãã³çæ³Â±
ãªããã·ããâ»1
ã
ã€ãã«ãããâ»2
å¯èœãªãã
åçš®é è¡å¹¹çŽ°è移æ€
FCçæ³Â±ãªããã·ããâ»1
ã
ãã³ãã ã¹ãã³çæ³
±ãªããã·ããâ»1
ïŒãé è¡åšè
«ç蚺çã¬ã€ãã©ã€ã³2013幎çãæ¥æ¬è¡æ¶²åŠäŒç·šãéååºçãåèã«äœæïŒ
4 æ
¢æ§ãªã³ãæ§çœè¡ç
ã§ã¯
ã©ã®ãããªæ²»çãè¡ãããã®ã§ãã
Q
AïŒæããå€ã«ããè¬ç©çæ³ã«ãã£ãŠç°åžžãªB现èãå¯èœãªéãæžããã
ããããç¶æ
ãé·ãç¶ãããšãç®æããŸããæ²»çæ¹éã¯ã幎霢ãå
šèº«ç¶æ
ã
æ¬äººã®åžæã17çªæè²äœã®æ¬ 倱ã®æç¡ã«ãã£ãŠç°ãªããŸãã
åºè©Šéšã®çµæãããšã«ç§åŠçã«æ€èšŒãããå°
é家ã®éã§åæãåŸãããŠãããçŸæç¹ã§æ
é©ãªæ²»çæ³ã§ãã
âæ²»çãéå§ããã«çµé芳å¯
ãæ¹èšRaiåé¡ã§äœãªã¹ã¯ãäžéãªã¹ã¯ãã
ãçœè¡ç
ã®æ²»çã¯ãæ¥æ¬è¡æ¶²åŠäŒãNCCN
ïŒäžçã®äž»èŠãªããã»ã³ã¿ãŒã®åçå£äœïŒã
ESMOïŒæ¬§å·èšåºè
«çåŠäŒïŒãäœæããã¬
ã€ãã©ã€ã³ã«ãã£ãŠæšæºåãããŠããŸãïŒå³
è¡š7ïŒãæšæºæ²»çã¯ãåœå
å€ã®ããããã®èš
- 13. å³è¡š10 æ
¢æ§ãªã³ãæ§çœè¡ç
ã®äž»ãªè¬ç©çæ³ã®å¯äœçš
è¬ç©çæ³ã®çš®é¡ è¬å€å äž»ãªå¯äœçš
FCR
çæ³
ãã«ãã©ãã³ã
ã·ã¯ããã¹ãã¡ããã
ãªããã·ããâ»ã
骚é«æå¶ãç¹ã«é節ãªå¥œäžçæžå°ãçœè¡çæžå°ã®é »åºŠãé«ããææçã«æ³šæã
å¿
èŠã貧è¡ãè¡å°æ¿æžå°ãåãæ°ã»ååãè±æ¯ãããŸããªã©ãçããããããŸ
ãã«é質æ§èºçãè³åºè¡ãäžæŽèãèµ·ããããšãããã
ãã³ãã ã¹ãã³
çæ³
ã¹ã³ãã ã¹ãã³ïŒå Žåã«ãã£
ãŠã¯ãªããã·ããâ»
ã䜵çšïŒ
奜äžçæžå°ãè¡å°æ¿æžå°ã貧è¡ãçºç±ãåŠæ æãåãæ°ã»ååãé£æ¬²äžæ¯ã䟿ç§
ãèµ·ããããããé質æ§èºçãè
«ç厩å£çå矀ãèµ·ããããšãããã
ã€ãã«ããã ã€ãã«ããã
èµ·ãããããå¯äœçšã¯äžç¢ãåãæ°ã奜äžçæžå°ãé¢ç¯çãé »åºŠã¯äœããæ¶å管
åºè¡ãé質æ§èºçã骚é«æå¶ãäžæŽèïŒå¿æ¿çŽ°åïŒãèµ·ããããšãããã
ïŒãæ£è
å¿
æºãåœç«ããç 究ã»ã³ã¿ãŒãã察çæ
å ±ã»ã³ã¿ãŒãªã©ãåèã«äœæïŒ
13
ãšã§ãããçšåºŠè»œæžã§ããããã«ãªã£ãŠããŠ
ããŸãã貧è¡ãã²ã©ããšãã«ã¯èŒžè¡ãå¿
èŠã«
ãªãããšããããŸããCLLã®æ£è
ããã¯ãã
ã ã§ããæ£åžžãªè¡æ¶²çŽ°èãæžå°ããŠããç¶æ
ã§ææçã«ããããããã®ã§ã骚é«æå¶ãåº
ãããæ²»çäžã¯ããã€ã以äžã«ææŽãããã
ãããã¹ã¯ã®ççšã人混ã¿ãé¿ãããšãã£ã
ææç察çãå¿ãããããšã倧åã§ãã
ãCLLã®æ²»çè¬ã«ã¯è±æ¯ãèµ·ããã«ããè¬
ãå€ãã®ã§ãããã·ã¯ããã¹ãã¡ãããªã©è±
æ¯ãçããããæããå€ã䜿ããšãæ²»çéå§
ãã2ã3é±éãããã§é«ªãçæ¯ããŸã€æ¯ãª
ã©ãæãå§ããŸãã髪ã®æ¯ãäœæ¯ã¯ãè±æ¯ã
ãããæããå€ã®æäžãçµããã°æ°ãæãã
å幎ãããã§å
ã®ç¶æ
ã«æ»ããŸãã
ãå
æããã¿ã€ãã®æããå€ã䜿ã£ãŠãããš
ãã«ã¯ãå¯äœçšãæããŠåæã«æžéãããäž
æ¢ãããããªãããã«ããŸãããã
ãé節ãªå¯äœçšãåºããšãã«ã¯ãå»åž«ã®å€æ
ã«ãã£ãŠããã£ããè¬ç©çæ³ãäžæ¢ããæã
ãå€ã®æžéãè¬ã®å€æŽãæ€èšããããšã«ãªã
ãŸãã
ãå¯äœçšã«ã¯ãèªåã§å¯ŸåŠã§ããããçšåºŠæ§
åãã¿ãŠãããå¯äœçšãšãããã«ç
é¢ãžé£çµ¡
ããã»ãããããã®ããããŸããè¬ç©çæ³ã
åããéã«ã¯ãå¯äœçšã®å¯ŸåŠæ³ãšãã©ããã
ãšãã«ç
é¢ãžé£çµ¡ãã¹ãããå¿
ã確èªããŠã
ããŸãããã
Patient's Voice
3
åç¥ãã5幎ãäžå®ãªæ°æã¡ãšæãåããä»ããŠå¿ç©ããã«
ã人éããã¯ã§çœè¡çå€ãé«ãããšã
ãããã倧åŠç
é¢ã§èª¿ã¹ããCLLãšã®
蚺æãæ°å€ä»¥å€ã«ç°åžžã¯ãªãããã£ãš
ç¡æ²»çã§ããå¥åº·ã«ã¯èªä¿¡ããã£ãã®
ã§ã蚺æãšåæã«èª¬æãããäœåœã®è©±
ãåãå
¥ããããã粟ç¥è
«çç§ã«ãé
ããŸãããå°æ¥ã®ããšãèãããšäžå®
ã§ãæ
å ±åéã«é§ãåãã人çã®æ®ã
æéãå°ãªããšæããŠæµ·å€æ
è¡ã«ãè¡
ãããšã«ãããã£ãšããŠããããŸãã
ã§ããããŸããçœè¡ç
æ£è
ã®æ¯æŽè
ã«
äŒãã骚é«ãã³ã¯ã®éãŸãã«ãåå ã
ãã®ãçžã§ä¿¡é Œã§ããå»åž«ã玹ä»ããŠ
ããã ãã人ã®ã€ãªããã«å©ããããŸ
ããã
ãäžå®ãæ±ããŠçããã®ã«ç²ãããšãã
ã人ã¯ãã£ãšåŒ·ããèªåã®åŒ·ããä¿¡ã
ãŠããããšãã粟ç¥è
«çå»ã®èšèãæ
ãã«ãªããŸãããè¡æ¶²å
ç§ãšç²Ÿç¥è
«ç
ç§ã«2人ã®äž»æ²»å»ãããããšã¯å¿ã®å®
å®ã«ã€ãªãã£ãŠããŸããåç¥ãã5幎ã
ããããã¯ç©ãããªåœããåã®ç掻ã
åãæ»ãããã§ãã
ïŒ58æ³å¥³æ§ã»èšºæãã5幎ç®ïŒ
â»
2018幎1æçŸåšãä¿éºæ¿èªãããŠããŸããã
äžèšã®ãããªçç¶ãçŸãããšãã«ã¯åœã«é¢ããå±éºæ§ããããŸãã
æ²»çãåããŠããå»çæ©é¢ãžé£çµ¡ããŸãããã
â38â以äžã®çºç±ã»æªå¯ãâåŒåžå°é£ãâåæžãæ¯èŠããã空å³ãç¶ã
âäžç¢ãã²ã©ãæ°Žåããšããªããâçèã ãããã¿ãã²ã©ã
å€éã»äŒæ¥ã®ç·æ¥æã®é£çµ¡å
ãšé£çµ¡æ¹æ³ãæ
åœå»ãçè·åž«ãè¬å€åž«ã«ç¢ºèªããŠããã
é»è©±ã®æšªãªã©ãããããå Žæã«é»è©±çªå·ãªã©ãã¡ã¢ããŠè²Œã£ãŠãããšå®å¿ã§ãã
ãããªçç¶ã
åºããšãã«ã¯
ããç
é¢ãž
é£çµ¡ãïŒ